Screener
Climb Bio, Inc. CLYM Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 4,287 | 7,269 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 47,768,543 and 47,766,338 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 5 | 5 |
| Additional paid-in capital | 451,372 | 449,762 |
| Accumulated other comprehensive income | 157 | 435 |
| Accumulated deficit | (303,449) | (289,727) |
| Total stockholders’ equity | 148,085 | 160,475 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s common stock?
- Climb Bio, Inc. (CLYM) reported common stock of $5K in Q1 2026.
- How has Climb Bio, Inc.'s common stock changed year-over-year?
- Climb Bio, Inc.'s common stock decreased by 28.6% year-over-year, from $7K to $5K.
- What is the long-term trend for Climb Bio, Inc.'s common stock?
- Over 5 years (2020 to 2025), Climb Bio, Inc.'s common stock has grown at a 38.0% compound annual growth rate (CAGR), from $1K to $5K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Climb Bio, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude